Alzheimer's Therapy
Alzheimer's Disease
Pre-clinicalActive
Key Facts
About Progenicyte Therapeutics
Progenicyte Therapeutics is a private, pre-clinical stage biotech targeting neurodegenerative diseases through a broad and vaguely defined approach involving stem cell therapy and activation. The company's public-facing information is limited and unpolished, listing a diverse and unconventional set of potential products including an oral stem cell activation drug, stem cell hair products, and therapies for Down Syndrome and Alzheimer's. This lack of focused pipeline detail, coupled with minimal corporate transparency, suggests it is an early-stage, pre-revenue venture with significant developmental and credibility risks ahead.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| itMSCs | Stemedica Cell Technologies | Clinical Development |
| Aucuba-001 | Aucuba Sciences | Preclinical |
| ALTA Drug Series | Alteron Therapeutics | Preclinical |
| NTRX-07 | NeuroTherapia | Phase 2 |
| 3D Neuronal Disease Models | BioTalentum | Research |
| Not Publicly Disclosed | Cerecin | Phase 1/2 |